ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)